PCDHB14

Across TCGA pan-cancer cohorts, PCDHB14 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated PCDHB14 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PCDHB14 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHB14 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

OV, UCEC, and SCLC are the cancer types where PCDHB14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.082	0.844	<.001	36	view →
UCEC	DFS	Median	All	0.975	0.609	<.001	36	view →
SCLC	OS	Median	II,III,IV	0.082	0.648	<.001	24	view →
BRCA	OS	Median	III,IV	0.198	0.833	<.001	18	view →
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
COAD	OS	Median	II,III,IV	0.392	0.799	.007	9	view →
SKCM	DFS	Median	IV	0.839	0.208	.009	9	view →
ESCA	OS	Median	All	0.224	0.564	.004	6	view →
STAD	OS	Median	IV	0.111	0.433	.002	3	view →
LIHC	OS	Median	All	0.144	0.704	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PCDHB14–OV (OS)

Open the OV breakdown →